In vivo efficacy and off-target effects of locked nucleic acid (LNA) and unlocked nucleic acid (UNA) modified siRNA and small internally segmented interfering RNA (sisiRNA) in mice bearing human tumor xenografts

Artificial DNA: PNA and XNA

Volumn 1, Issue 1, 2010, Pages 36-44

  Mook, O R F ^a   Vreijling, Jeroen ^b   Wengel, Suzy L ^c   Wengel, Jesper ^d   Zhou, Chuanzheng ^e   Chattopadhyaya, Jyoti ^e   Baas, Frank ^b   Fluiter, Kees ^a,b  

^a Macrozyme BV   (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

^c RiboTask ApS ^*  (Denmark)

^d UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^e UPPSALA UNIVERSITY   (Sweden)

Author keywords

LNA; Off target effects; SiRNA; SisiRNA; Unlocked nucleic acid

Indexed keywords

ANTINEOPLASTIC AGENT; LOCKED NUCLEIC ACID; NUCLEIC ACID; SMALL INTERFERING RNA; SMALL INTERNALLY SEGMENTED INTERFERING RNA; UNCLASSIFIED DRUG; UNLOCKED NUCLEIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHEMICAL MODIFICATION; CONTROLLED STUDY; DRUG DISTRIBUTION; DRUG EFFECT; DRUG EFFICACY; DRUG FORMULATION; DRUG MECHANISM; DRUG TARGETING; DRUG TISSUE LEVEL; FEMALE; GENE CONTROL; GENE SILENCING; GENOME ANALYSIS; HUMAN; HUMAN CELL; IN VIVO STUDY; MOUSE; NONHUMAN; SUBCUTANEOUS TISSUE TUMOR; TUMOR XENOGRAFT;

MUS;

EID: 79952180442     PISSN: 1949095X     EISSN: 19490968     Source Type: Journal    
DOI: 10.4161/adna.1.1.12204     Document Type: Article

References (30)

1. Bramsen JB, Laursen MB, Nielsen AF, Hansen TB, Bus C, Langkjaer N et al. A large-scale chemical modification screen identifies design rules to generate siRNAs with high activity, high stability and low toxicity. Nucleic Acids Res 2009; 3:2867-2881.
2. Elbashir SM, Harborth J, Lendeckel W, Yalcin A, Weber K, Tuschl T. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 2001; 411:494-498.
3. Jackson AL, Burchard J, Schelter J, Chau BN, Cleary M, Lim L et al. Widespread siRNA "off-target" transcript silencing mediated by seed region sequence complementarity. RNA 2006; 12:1179-1187.
4. Marques JT, Williams BR. Activation of the mammalian immune system by siRNAs. Nat Biotechnol 2005; 23:1399-1405.
5. Elmen J, Thonberg H, Ljungberg K, Frieden M, Westergaard M, Xu Y et al. Locked nucleic acid (LNA) mediated improvements in siRNA stability and functionality. Nucleic Acids Res 2005; 33:439-447.
6. Bramsen JB, Laursen MB, Damgaard CK, Lena SW, Babu BR, Wengel J et al. Improved silencing properties using small internally segmented interfering RNAs. Nucleic Acids Res 2007; 35:5886-5897.
7. Hornung V, Guenthner-Biller M, Bourquin C, Ablasser A, Schlee M, Uematsu S et al. Sequence-specific potent induction of IFNα by short interfering RNA in plasmacytoid dendritic cells through TLR7. Nature Med 2005; 11:263-270.
8. Judge AD, Bola G, Lee AC, MacLachlan I. Design of noninflammatory synthetic siRNA mediating potent gene silencing in vivo. Mol Ther 2006; 13:494-505.
9. Robbins M, Judge A, Liang L, McClintock K, Yaworski E, MacLachlan I. 2'-O-methyl-modified RNAs act as TLR7 antagonists. Mol Ther 2007; 15:1663-1669.
10. Langkjaer N, Paternak A, Wengel J. UNA (unlocked nucleic acid): a flexible RNA mimic that allows engineering of nucleic acid duplex stability. Bioorg Med Chem 2009; 17:5420-5425.
11. Vester B, Wengel J. LNA (locked nucleic acid): high-affinity targeting of complementary RNA and DNA. Biochemistry 2004; 43:13233-13241.
12. Mook OR, Baas F, de Wissel MB, Fluiter K. Evaluation of locked nucleic acid-modified small interfering RNA in vitro and in vivo. Mol Cancer Ther 2007; 6:833-843.
13. Anderson EM, Birmingham A, Baskerville S, Reynolds A, Maksimova E, Leake D et al. Experimental validation of the importance of seed complement frequency to siRNA specificity. RNA 2008; 14:853-861.
14. Jackson AL, Burchard J, Leake D, Reynolds A, Schelter J, Guo J et al. Position-specific chemical modification of siRNAs reduces "off-target" transcript silencing. RNA 2006; 12:1197-1205.
15. Duxbury MS, Matros E, Ito H, Zinner MJ, Ashley SW, Whang EE. Systemic siRNA-mediated gene silencing: a new approach to targeted therapy of cancer. Ann Surg 2004; 240:667-674.
16. Liang Z, Yoon Y, Votaw J, Goodman MM, Williams L, Shim H. Silencing of CXCR4 blocks breast cancer metastasis. Cancer Res 2005; 65:967-971.
17. Glud SZ, Bramsen JB, Dagnaes-Hansen F, Wengel J, Howard KA, Nyengaard JR, Kjems J. Naked siLNA-mediated gene silencing of lung bronchoepithelium EGFP expression after intravenous administration. Oligonucleotides 2009; 19:163-168.
18. Tiemann K, Rossi JJ. RNAi-based therapeutics-current status, challenges and prospects. EMBO Mol Med 2009; 1:142-151.
19. Khan AA, Betel D, Miller ML, Sander C, Leslie CS, Marks DS. Transfection of small RNAse globally perturbs gene regulation by endogenous microRNAs. Nature Biotech 2009; 27:549-555.
20. Kleinman ME, Yamada K, Takeda A, Chandrasekaran V, Nozaki M, Baffi JZ et al. Sequence- and target-independent angiogenesis suppression by siRNA via TLR3. Nature 2008; 452:591-597.
21. Burchard J, Jackson AL, Malkov V, Needham RH, Tan Y, Bartz SR et al. MicroRNA-like off-target transcript regulation by siRNAs is species specific. RNA. RNA 2009; 15:308-315.
22. Beaucage SL, Caruthers MH. In Current Protocols in Nucleic Acid Chemistry 2001, ed. Beaucage SL, John Wiley & Sons, Inc., New Jersey US, Ch 3, Unit 3.3.
23. Nielsen P, Dreiøe LH, Wengel J. Synthesis and evaluation of oligodeoxynucleotides containing acyclic nucleosides: introduction of three novel analogues and a summary. Bioorg Med Chem 1995; 3:19-28.
24. Srivastava P, Barman J, Pathmasiri W, Plashkevych O, Wenska M, Chattopadhyaya J. Five- and six-membered conformationally locked 2', 4'-carbocyclic ribo-thymidines: synthesis, structure and biochemical studies. J Am Chem Soc 2007; 129:8362-8379.
25. Zhou C, Honcharenko D, Chattopadhyaya J. 2-(4-Tolylsulfonyl)ethoxymethyl (TEM)-a new 2'-OH protecting group for solid-supported RNA synthesis. Org Biomol Chem 2007; 5:333-343.
26. Zhou C, Pathmasiri W, Honcharenko D, Chatterjee S, Barman J, Chattopadhyaya J. High-quality oligo-RNA synthesis using the new 2'-O-TEM protecting group by selectively quenching the addition of p-tolyl vinyl sulphone to exocyclic amino functions. Can J Chem 2007; 85:293-301.
27. Fluiter K, ten Asbroek ALMA, van Groeningen M, Nooij M, Aalders MCG, Baas F. Tumor genotype-specific growth inhibition in vivo by antisense oligonucleotides against a polymorphic site of the large subunit of human RNA polymerase II. Cancer Res 2002; 62:2024-2028.
28. Church GM, Gilbert W. Genomic sequencing. Proc Natl Acad Sci USA 1984; 81:1991-1995.
29. Graham MJ, Freier SM, Crooke RM, Ecker DJ, Maslova RN, Lesnik EA. Tritium labeling of antisense oligonucleotides by exchange with tritiated water. Nucleic Acids Res 1993; 21:3737-3743.
30. Bijsterbosch MK, Manoharan M, Rump ET, De Vrueh RL, van Veghel R, Tivel KL et al. In vivo fate of phosphorothioate antisense oligodeoxynucleotides: predominant uptake by scavenger receptors on endothelial liver cells. Nucleic Acids Res 1997; 25:3290-3296.